UY39569A - N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas - Google Patents

N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas

Info

Publication number
UY39569A
UY39569A UY0001039569A UY39569A UY39569A UY 39569 A UY39569 A UY 39569A UY 0001039569 A UY0001039569 A UY 0001039569A UY 39569 A UY39569 A UY 39569A UY 39569 A UY39569 A UY 39569A
Authority
UY
Uruguay
Prior art keywords
compounds
salts
cyanothiazolidin
carboxamides
oxoethyl
Prior art date
Application number
UY0001039569A
Other languages
English (en)
Spanish (es)
Inventor
Jonas Branalt
Bjorn Holm
Maria Johansson
Olle Karlsson
Anneli Nordqvist
Marianne Swanson
Laurent Knerr Daniel
John Sheppard Robert
Anna Tomberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY39569A publication Critical patent/UY39569A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001039569A 2020-12-17 2021-12-16 N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas UY39569A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063126593P 2020-12-17 2020-12-17

Publications (1)

Publication Number Publication Date
UY39569A true UY39569A (es) 2022-07-29

Family

ID=79164845

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039569A UY39569A (es) 2020-12-17 2021-12-16 N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas

Country Status (20)

Country Link
US (2) US20240101549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263535A1 (cg-RX-API-DMAC7.html)
JP (2) JP7622229B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230122080A (cg-RX-API-DMAC7.html)
CN (1) CN116745291B (cg-RX-API-DMAC7.html)
AR (1) AR124379A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021403827B2 (cg-RX-API-DMAC7.html)
CA (1) CA3204318A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001763A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008921A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230314A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000124A (cg-RX-API-DMAC7.html)
EC (1) ECSP23053033A (cg-RX-API-DMAC7.html)
IL (1) IL303655A (cg-RX-API-DMAC7.html)
MX (1) MX2023007287A (cg-RX-API-DMAC7.html)
PE (1) PE20232046A1 (cg-RX-API-DMAC7.html)
SA (1) SA523441175B1 (cg-RX-API-DMAC7.html)
TW (1) TW202239407A (cg-RX-API-DMAC7.html)
UY (1) UY39569A (cg-RX-API-DMAC7.html)
WO (1) WO2022130270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
AU2023288645A1 (en) * 2022-06-21 2025-02-13 Astrazeneca Ab Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide
CN119562951A (zh) * 2022-06-21 2025-03-04 阿斯利康(瑞典)有限公司 N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺
WO2026119802A1 (en) 2024-12-02 2026-06-11 Astrazeneca Ab Dosing regimen for the treatment of fap-mediated conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW521072B (en) 1997-06-02 2003-02-21 Meiji Seika Kaisha 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
AU2001277754B2 (en) 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
JP2003026698A (ja) 2000-09-27 2003-01-29 Tokyo Inst Of Technol 新規化合物、固定化物及び蛋白質のスクリーニング方法
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2004207731B2 (en) 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
TWI366438B (en) 2004-08-12 2012-06-21 Ishihara Sangyo Kaisha Fungicidal composition containing acid amide derivative
WO2007017423A2 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
JP2010510246A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
CN102884059B (zh) 2010-03-11 2015-08-26 大日本住友制药株式会社 N-酰基环胺衍生物或其可药用盐
EP4706663A3 (en) 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
EP2874632B1 (en) 2012-07-23 2020-06-17 Sphaera Pharma Pte. Ltd Triazine compound having pi3k-alpha and mtor inhibiting activity
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
JP2017513954A (ja) 2014-04-22 2017-06-01 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016061751A1 (en) * 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN108690043B (zh) 2017-04-11 2019-10-18 东莞东阳光科研发有限公司 喹啉类衍生物及其制备方法和用途
US11358940B2 (en) 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
US11584744B2 (en) 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
AU2018386298B2 (en) 2017-12-15 2023-09-07 Praxis Biotech LLC Inhibitors of fibroblast activation protein
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Tlr7/8アンタゴニストおよびそれらの使用
PH12020551205A1 (en) 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
SG11202100818RA (en) 2018-07-31 2021-02-25 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US12662494B2 (en) 2018-08-08 2026-06-23 Sumitomo Pharma Co., Ltd. Optically active bridged piperidine derivative
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
US12559487B2 (en) 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
BR112022008041A2 (pt) 2019-11-06 2022-08-16 Yuhan Corp Compostos de pirrolidina e piperidina
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas

Also Published As

Publication number Publication date
DOP2023000124A (es) 2023-07-09
US20240101549A1 (en) 2024-03-28
MX2023007287A (es) 2023-07-03
WO2022130270A1 (en) 2022-06-23
EP4263535A1 (en) 2023-10-25
AU2021403827A1 (en) 2023-07-27
JP7744538B2 (ja) 2025-09-25
CO2023008921A2 (es) 2023-07-21
AU2021403827B2 (en) 2024-07-25
JP2025081297A (ja) 2025-05-27
ECSP23053033A (es) 2023-08-31
TW202239407A (zh) 2022-10-16
US11858924B2 (en) 2024-01-02
CL2023001763A1 (es) 2023-11-17
CN116745291B (zh) 2026-06-30
IL303655A (en) 2023-08-01
PE20232046A1 (es) 2023-12-27
CR20230314A (es) 2023-08-18
CA3204318A1 (en) 2022-06-23
US20230312550A1 (en) 2023-10-05
KR20230122080A (ko) 2023-08-22
AU2021403827A9 (en) 2024-10-17
SA523441175B1 (ar) 2024-08-29
JP7622229B2 (ja) 2025-01-27
AU2024219819B2 (en) 2026-06-04
JP2023554405A (ja) 2023-12-27
AU2024219819A1 (en) 2024-10-10
CN116745291A (zh) 2023-09-12
AR124379A1 (es) 2023-03-22

Similar Documents

Publication Publication Date Title
CL2023001763A1 (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
CL2009000324A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
CL2023001367A1 (es) Inhibidores de btk
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
EA201001517A1 (ru) Замещенные пиперидины в качестве терапевтических соединений
AR108389A2 (es) Derivados de ácido fenilacético
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
BR112022005723A2 (pt) Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas